Abstract OBJECTIVE: To evaluate the efficacy and safety of the ICE regimen (iphosphamide + carboplatin+etoposide) used in treating children with hepatoblastoma in the Shanghai Children's Medical Center. METHODS: From June 2000 to June 2008, 14 children with newly diagnosed hepatoblastoma (7 males and 7 females) were enrolled. Their median age on diagnosis was 1.33 years (range: 0.25-8.25 years). Six patients had stage I disease, 1 had stage II, 5 had stage III, and 2 had stage IV diseases. Thirteen children had markedly increased serum AFP level, and 1 had normal serum AFP level. Multidisciplinary co-operation treatment was performed. Eight patients had primary surgery while 3 patients had pre-operation chemotherapy before surgery. ICE chemotherapy regimen was used. Totally, 73 courses of chemotherapy were administered for the 14 children and 25 out of the 73 courses were performed before operation. RESULTS: Twelve patients responded to the treatment (85.7%) and 2 failed. Ten patients (71.4%) achieved complete remission after treatment, and two had partial remission. By July 31st, 2008, 9 patients survived without any event, with a median follow-up duration of 35 months (range: 16-96 months). The 5-year overall survival rate was 70.71±12.37%, and the 5-year event-free survival rate was 64.29±12.81%. One patient had disease relapse and two patients were lost to follow-up after they achieved partial remission. CONCLUSIONS: The ICE regimen combined with operation is effective and safe in treating children with hepatoblastoma.［Chin J Contemp Pediatr, 2009, 11 (8):659-662］
PAN Ci,TANG Jing-Yan,CHEN Jing et al. Clinical observation on the treatment outcome of 14 children with hepatoblastoma in a single medical center[J]. 中国当代儿科杂志, 2009, 11(08): 659-662.
PAN Ci,TANG Jing-Yan,CHEN Jing et al. Clinical observation on the treatment outcome of 14 children with hepatoblastoma in a single medical center[J]. CJCP, 2009, 11(08): 659-662.
［1］Roebuck DJ, Perilongo G. Hepatoblastoma: an oncological review［J］. Pediatr Radiol, 2006, 36(3):183-186.
［2］Warmann SW, Fuchs J. Drug resistance in hepatoblastoma［J］. Curr Pharm Biotechnol, 2007, 8(2):93-97.
［3］Malogolowkin MH, Katzenstein HM, Krailo M, Chen Z, Quinn JJ, Reynolds M, et al. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma［J］.J Clin Oncol, 2008, 26(14):2379-2383.
［4］Malogolowkin MH, Katzenstein H, Krailo MD, Chen Z, Bowman L, Reynolds M, et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma［J］. J Clin Oncol, 2006, 24(18):2879-2884.
［5］Blouin P, Brugières L, Tabone MD, Leverger G, Rubie H, Branchereau S, et al. Carboplatin-epirubicin regimen for the treatment of hepatoblastoma［J］. Pediatr Blood Cancer, 2004, 42(2):149-154.
［6］Suita S, Tajiri T, Takamatsu H, Mizote H, Nagasaki A, Inomata Y, et al. Improved survival outcome for hepatoblastoma based on an optimal chemotherapeutic regimen-a report from the study group for pediatric solid malignant tumors in the Kyushu area［J］.J Pediatr Surg, 2004, 39(2):195-198.
